{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4LrxuLsJDA","lastupdate":"2023-12-04T00:00:00.000Z","update_date":"2023-12-04T00:00:00.000Z","lastModified":"Jun 4, 2024","active":1,"confidence_score":90,"confidence_score_reason":"markets, not claimed","urlname":"nanoghosts","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$oCJbbFZF7VF2IL793hzjaeuuo5xWPbcDCctdSWpBWXbNKF0c53fe9e","name":"NanoGhost","oneliner":"Naturally Targeted Drug Platform","registrar":"516071149","website":"https://www.nano-ghost.com/","careerspage":"https://www.nano-ghost.com/careers","founded_month":8,"founded_year":2019,"formernames":["Nano Ghosts"],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/80018810","instagram":""},"social":["https://www.linkedin.com/company/80018810"],"flattenedsociallinks":"https://www.linkedin.com/company/80018810","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"11-50","employees_exact":12,"patent":1,"raised":9000000,"stage":"Seed","public_stage":"Seed","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Nano-Ghosts","Nano.Ghost","NanoGhosts","NanoGhost"],"about":"NanoGhost is a drug-delivery technology that uses adult stem cells to transport medicine directly to the tumor site. The technology has already proven successful in treating pancreatic, lung, breast, prostate, and brain cancer in mice.\r\n\r\nThe platform is based on nano-vesicles, termed Nano-Ghosts (NGs), which are technologically reconstructed from the cell membranes of naturally targeted allogeneic mesenchymal stem cells (MSCs), after removing their cytoplasm and nuclei. The NGs' safety and targeting capabilities rely on their retention of the surface-associated mechanisms that govern MSCs' well-documented allogeneic tolerability and targeting of multiple inflamed and malignant tissues. \r\n\r\nThe NanoGhost technology was developed by Professor Marcel Machluf, the faculty dean of Biotechnology & Food Engineering at the Technion-Israel Institute of Technology. Professor Machluf developed the technology in her lab at the Technion and set up a start-up as a spin-off from the university to commercialize the technology.\r\n\r\nIsrael's Ministry of Science and Technology named NanoGhost as one of Israel's 60 most impactful developments. The NanoGhost technology has been patented in the United States and Europe, with additional patents pending in India and China.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"15f86319-8131-48b5-9a12-a0642c7673a6","city":"Netanya","type":null,"address":"Beni Ga'on St 12, Netanya, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"5JJCpk7dGAY7QyRK9STCt3vihdBFa9ghK8RZZBM4PHtsTOEUKshHCC","date":"Nov 28, 2021","link":"https://www.israel21c.org/how-to-reduce-cancer-drug-dosage-a-millionfold/","source":"www.israel21c.org","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"KAbUUe4sqqhW7tcSIX6W4NFoOoXFhyCLdL9rADKXK44cn0PSAKrpXS","news_summary":"How to reduce cancer drug dosage a millionfold - ISRAEL21c","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"81c3295e-1525-40bd-a0d2-46ba7112a93a","date":"Jun 22, 2021","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3910667,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"medicine delivery system","company":"NanoGhost","layoffs":null,"summary":"NanoGhost, a company founded by Prof. Marcelle Machluf and Yonatan Malca, is developing a drug-delivery technology based on adult stem cells. The technology, called NanoGhost, uses modified adult stem cells loaded with medicine to target cancer cells. The stem cells are emptied and shrunk to nano-size, creating nano-ghost vesicles that act as trojan horses to deliver medicine directly to the cancer cells. NanoGhost has raised $5 million in its seed round, with aMoon serving as a lead investor. The company aims to reach animal testing within a year and conduct clinical trials by 2023. The founders emphasize that there is still work to be done, but they believe the system works and will be effective in humans.","partners":null,"customers":null,"investors":"aMoon","confidence":8,"key_topics":["cancer","drug-delivery technology","clinical trials","stem cells","nanovesicles"],"date_of_event":"June 22, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$5 million","structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WwIew0P6swVT2GxB4qIXuRz48ycO0tmh1MJvUHUWb5nYnOtRMzME7K","news_summary":"NanoGhost: Delivering the greatest things in the smallest packages","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"98ba7298-f6ae-4a39-84fd-3300c6d68cbc","date":"May 20, 2020","link":"https://ats.org/our-impact/prof-marcelle-machluf-is-adapting-her-nano-ghost-research-to-trap-covid-19/3/","source":"ats.org","visible":1,"analysis":{"tags":"research","company":"Technion","summary":"Technion Professor Marcelle Machluf has adapted her nano-ghost research to trap COVID-19. The companys growth is expected to be positive as a result of this research adaptation. The key theme of the article is research. The key issues discussed in the article are expansion and recruitment. The event described in the article does not have a specific date mentioned. The confidence level of the answer is 8.","investors":null,"key_topics":["Technion","COVID-19","research","nano-ghost","adaptation"],"impact_on_company":"growth-positive","structured_issues":["Expand"],"structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"wtYBBt5foNxXHz4MM6Qs8lCA8Z1xsovub2OLPKZ6hGPZuWxVHTy4Md","news_summary":"Prof. Marcelle Machluf Is Adapting Nano-Ghost Research to Trap COVID-19 - American Technion Society","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7b418a8a-6678-43fe-bad5-934e55b415eb","date":"Dec 24, 2019","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3776429,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"drug delivery system, cancerous tumors","company":"NanoGhosts","layoffs":null,"summary":"Israel-based life sciences, healthcare, and technology venture capital firm aMoon, together with an unnamed private investor, invested $5 million in cancer drug startup NanoGhosts. NanoGhosts turns stem cells into a drug delivery system that specifically targets cancerous tumors. The technology is based on the founders research at the Technion Israel Institute of Technology. NanoGhosts research has shown promising results in prolonging the survival of animals with cancer. AMoon is a venture capital firm founded in 2016 and its portfolio includes other healthcare and technology companies.","partners":null,"customers":null,"investors":"aMoon, unnamed private investor","confidence":9,"key_topics":["NanoGhosts","drug delivery system","cancerous tumors","investment","research"],"date_of_event":"24.12.19","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$5 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"uIwnOxpHbcT2fur6sMB3SxcMnkSWI1zp858hjnp8e7CqjgpNFPWJ4F","news_summary":"Life Sciences Venture Fund aMoon Invests $5 Million in Cancer Drug Company","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"14b51968-000a-4193-a98a-dfa8cd0cf139","date":"Dec 23, 2019","link":"https://www.timesofisrael.com/ghost-cell-startup-that-targets-deadliest-cancers-gets-funding-boost/","source":"www.timesofisrael.com","visible":1,"analysis":{"tags":"investment","company":"aMoon","layoffs":null,"summary":"aMoon, a health-tech fund, has made a $5 million investment in a new venture set up by Prof. Marcelle Machluf to develop her NanoGhost technology, which aims to shrink the deadliest forms of cancer by precisely targeting the tumors. The NanoGhost technology, developed by Machluf at the Technion-Israel Institute of Technology, uses mesenchymal stem cells to create nano-vehicles filled with anti-cancer drugs that are injected into the bloodstream and released directly into the tumors. Lab experiments have shown promising results in reducing tumor size. aMoons investment will support the commercialization of the technology.","partners":null,"customers":null,"investors":"private investor from the US","confidence":8,"key_topics":["aMoon","investment","health-tech","life sciences","NanoGhost technology"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$5 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UsBeJuCBfzs3K9VaN4fl6phqUEa3S69tvBRFyA7gBHtig5aF7hfMeV","news_summary":"'Ghost' cell startup that targets deadliest cancers gets funding boost","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"304f572f-a38d-4f35-af10-199ca730d649","date":"Apr 21, 2019","link":"https://www.jewishexponent.com/2019/04/21/marcelle-machluf-nanoghosts/","source":"www.jewishexponent.com","visible":1,"analysis":{"tags":["cancer treatment"],"company":"Technion-Israel Institute of Technology","layoffs":null,"summary":"Marcelle Machluf, the dean of biotechnology and food engineering at the Technion-Israel Institute of Technology, is working on an innovative cancer treatment called nanoghosts. Nanoghosts, a drug-delivery technology that uses adult stem cells to transport medicine directly to the tumor site, have already proven successful in treating various types of cancer in mice. The technology has won Machluf numerous honors and awards. The next step is to raise funds for the company and proceed to clinical trials. Machluf believes that nanoghosts have the potential to be a game changer in the field of cancer treatment, improving drug efficacy and reducing side effects. She also discusses her experiences as a woman and minority in the field of science and offers advice to others interested in pursuing STEM.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["nanoghosts","cancer treatment","drug delivery","STEM","honors and awards"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"YCtdmXzoYkIZirqOWpFuVZoLDZslWeiXd7ky20A8IdOqGjGmFqFIwx","news_summary":"Israeli Scientist Discusses Cancer Treatment - Jewish Exponent","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3db690a6-4fd2-4dc0-85f3-24b9a0766893","date":"Apr 29, 2018","link":"https://www.jpost.com/HEALTH-SCIENCE/The-woman-behind-nanoghosts-552974","source":"www.jpost.com","visible":1,"analysis":{"tags":"medical research","company":"Technion-Israel Institute of Technology","layoffs":null,"summary":"Prof. Marcelle Machluf, a scientist at the Technion-Israel Institute of Technology, had her medical articles initially rejected by journals but has since been recognized for her research on tissue engineering and cancer drug delivery. Her lab studies have shown that her modified stem cells called nanoghosts can kill every type of solid tumor. The rejection by journals was seen as a growth-negative impact on the company, but the subsequent recognition and publication of her work have had a growth-positive impact. The key theme of the article is the achievements and contributions of Prof. Marcelle Machluf in the field of medical research. The key issues discussed in the article are related to customers, as the article mentions the testing of her lab studies on patients in the next year or two. The date of the event described in the article is not specified. The confidence in the answer is 8.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["medical research","cancer treatment","stem cells","nanoghosts","scientific achievements"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"p9fls2kVmQEPp6stEakNyfs8LhGImnRvWmwxE6HIRw0BkmAmbMLyjZ","news_summary":"https://www.jpost.com/HEALTH-SCIENCE/The-woman-behind-nanoghosts-552974","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":7,"techcommunityinvolvement":null,"mediagallery":[{"id":"9fb7e1ec-ee64-4914-94c2-de5699e84f44","timestamp":"2020-12-02 15:56:40.000000","resources_type":2,"resources_title":"","resources_file_name":"dAu0F8mJwp0","alt":"","imageurl":"https://img.youtube.com/vi/dAu0F8mJwp0/0.jpg","url":"http://youtu.be/dAu0F8mJwp0"},{"id":"77f3cfed-b7a4-47fa-aefa-6e17e504a011","timestamp":"2020-05-31 14:57:26.000000","resources_type":2,"resources_title":"Technion Prof. Marcelle Machluf Nano-Ghosts to Trap Coronavirus","resources_file_name":"koxdcMVnDA4","alt":"Technion Prof. Marcelle Machluf Nano-Ghosts to Trap Coronavirus logo","imageurl":"https://img.youtube.com/vi/koxdcMVnDA4/0.jpg","url":"http://youtu.be/koxdcMVnDA4"},{"id":"1bc68e8c-77d1-44e2-9e71-0e4042174841","timestamp":"2019-12-25 07:30:01.000000","resources_type":1,"resources_title":"NanoGhosts","resources_file_name":"$iUhRzIh9rg4faFZumOcsWehv2C9ncYYoqCsYNn149mXfK1d2wqdRWo","alt":"NanoGhosts logo","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$iUhRzIh9rg4faFZumOcsWehv2C9ncYYoqCsYNn149mXfK1d2wqdRWo","url":"https://storage.googleapis.com/clean-finder-353810/$iUhRzIh9rg4faFZumOcsWehv2C9ncYYoqCsYNn149mXfK1d2wqdRWo"}],"tags":["targeted-cancer-therapy","cancer","targeted-therapy","stem-cells","drug-delivery","nanotechnology","immunotherapy","treatments","pharmaceuticals","biotechnology","genetics"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"technologysuccessstory":[{"date":"2007-01-01","name":"Highly selective targeted delivery platform based on unique cell-derived nano-vesicles ","tags":["drug-delivery","stem-cells","cancer-therapy","treatments","patent-pending"],"category":"Pharmaceuticals & Diagnostics","tto_logo":"/image_cloud/t3_tto_logo_f5fde2b3-6016-11e8-abf1-41fdcbb0dda6","university_logo":"/image_cloud/t3_institution_logo_f5fde2b3-6016-11e8-abf1-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2B"],"productstage":"R&D","products":[],"geomarkets":["Europe","India","China","United States"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":2,"lastfunding":"$4M","totalrounds":2,"fundingstage":"Seed","totalfunding":"$9M","publicinvestors":2,"lastpublicfunding":4000000,"totalpublicrounds":2,"totalpublicfunding":9000000},"team":[{"name":"Yonatan Malca","email":"yonatan@nano-ghost.com","phone":"050-739-1691","gender":"Male","userid":"Mhn8d0jcBGGx1h71jjcHcVlSd5tTVa4S2B8w8Kiw4wqGt6ldANn8CI","bounced":false,"claimed":1,"founder":0,"urlname":"yonatan-malca","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgupPCygkM","position":"CEO","last_name":"Malca","claimtoken":"itF0CBjV3F1OEa0hwRjMS8pCrKAke2aqezXdqrHonwCXT5l5cY90YF","first_name":"Yonatan","picturekey":null,"claimeddate":"2024-06-04","linkedinurl":"https://www.linkedin.com/in/yonatan-malca-145a68202/","unsubscribed":false,"is_activeuser":1,"additionalemail":"yonmalca@gmail.com","claimedemaildate":"2024-03-19 15:49:46.000000","initials":"YM","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Prof. Marcel Machluf","email":"machlufm@technion.ac.il","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4LrxouYLDA","bounced":false,"claimed":0,"founder":1,"urlname":"prof-marcel-machluf","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg2vaGhgsM","position":"Founder & inventor","last_name":"Machluf","claimtoken":"gNxOC4jKwWcId6yxTxb4bys3Mwhb4Z321Wh8UjVSXPgc9XEIlURFPF","first_name":"Prof. Marcel","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-11-16 13:36:12.000000","initials":"PM","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Osnat Bohana Kashtan","email":"osnat@nano-ghost.com","phone":"","gender":"Female","userid":"yQ34WJ7lf14tKIwpMDbXu84ph7vLIf7NdvRepWdLJ5RWjlj8Ck3Q9f","bounced":false,"claimed":null,"founder":0,"urlname":"osnat-bohana-kashtan-1","visible":1,"memberid":"h9Vyr2f2Hvep5vvijm78B2F6vd7bwMAfvbBrhtWeFYkoidMGJ4VBaj","position":"VP R&D","last_name":"Bohana Kashtan","claimtoken":"hk8cP4XD1xZuK3UIwHl0v9pKfEnWUyX0xrWsIlB0tURTyfgcmqVwx7","first_name":"Osnat","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/osnat-bohana-kashtan-775a785/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2023-12-04 13:16:01.000000","initials":"OB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNbc3s0KDA","fullname":"Hilla Gorokhovsky"},"biverifydate":"2020-05-31T00:00:00.000Z","crunchbaseid":"","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Yotam Maman","creator_email":"yotamm1988@gmail.com","createdate":"2019-12-25T00:00:00.000Z","biverification":"Hilla Gorokhovsky","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"4hYn38HIc5pneBfPYi6DNkFLvn7W4rNB6HeYtPcRFS5WACJTzO4FWB","date":"Jun 2023","amount":"$4M","source":"Alex Shilman from New Gate Capital","eventtype":"FundingRoundEvent","investment":[{"name":"New Gate Capital","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/new-gate-capital","logokey":"$ewuh5iR9B6AU9Tu07nRlN3AkqiOcBak1OQRYKIbBqgrpJ7mM4Mt1qR","tagline":null,"urlname":"/investor_page/new-gate-capital","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkMjo_P8JDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"JCs3HGhHKqThnPYdLeIEHXC4ZYewQ7ivGvboSeffGdk93RNO7zDdDF","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ewuh5iR9B6AU9Tu07nRlN3AkqiOcBak1OQRYKIbBqgrpJ7mM4Mt1qR","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":4000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCGtI_WCww","date":"Dec 2019","amount":"$5M","source":"https://www.calcalistech.com/ctech/articles/0,7340,L-3776429,00.html","eventtype":"FundingRoundEvent","investment":[{"name":"aMoon Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/amoon-partners","logokey":"$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","tagline":null,"urlname":"/investor_page/amoon-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIj37p8KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"67d08fcf-d1fa-4131-a73b-73fb286fc4ec","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"8/2019","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"NanoGhost","logourl":"https://storage.googleapis.com/clean-finder-353810/$oCJbbFZF7VF2IL793hzjaeuuo5xWPbcDCctdSWpBWXbNKF0c53fe9e","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$oCJbbFZF7VF2IL793hzjaeuuo5xWPbcDCctdSWpBWXbNKF0c53fe9e","seoabout":"NanoGhost is a drug-delivery technology that uses adult stem cells to transport medicine directly to the tumor site. The technology has already proven succ...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology"}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Materials & Substances","key":"0-0","path":"TechnologyClassificationModel>Materials & Substances"},{"title":"Biologicals","key":"0-1","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Cells","key":"0-1-0","path":"TechnologyClassificationModel>Biologicals>Cells"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology"],"coreTechnology":["Materials & Substances","Biologicals","Cells"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"4hYn38HIc5pneBfPYi6DNkFLvn7W4rNB6HeYtPcRFS5WACJTzO4FWB","date":"Jun 2023","amount":"$4M","source":"Alex Shilman from New Gate Capital","eventtype":"FundingRoundEvent","investment":[{"name":"New Gate Capital","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/new-gate-capital","logokey":"$ewuh5iR9B6AU9Tu07nRlN3AkqiOcBak1OQRYKIbBqgrpJ7mM4Mt1qR","tagline":null,"urlname":"/investor_page/new-gate-capital","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkMjo_P8JDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"JCs3HGhHKqThnPYdLeIEHXC4ZYewQ7ivGvboSeffGdk93RNO7zDdDF","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ewuh5iR9B6AU9Tu07nRlN3AkqiOcBak1OQRYKIbBqgrpJ7mM4Mt1qR","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":4000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCGtI_WCww","date":"Dec 2019","amount":"$5M","source":"https://www.calcalistech.com/ctech/articles/0,7340,L-3776429,00.html","eventtype":"FundingRoundEvent","investment":[{"name":"aMoon Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/amoon-partners","logokey":"$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","tagline":null,"urlname":"/investor_page/amoon-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIj37p8KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"67d08fcf-d1fa-4131-a73b-73fb286fc4ec","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}